EU-MEDICAL_DEVICES_REGULATION-ANX_I_SEC_10
EU-MEDICAL_DEVICES_REGULATION-ANX_I_SEC_10
Medical Devices Regulation - Hazardous Substances
EU. Hazardous Substances for Purposes of Medical Devices Regulation 2017/745/EU, 5 May 2017, as amended by Regulation 2020/561/EU, 24 April 2020
This list contains hazardous substances for purposes of the Medical Devices Regulation (MDR), based on the legislation's Annex I general safety and performance requirements, including for chemical, physical and biological properties. Specifically, the non-exhaustive database is derived from: Table 3 of Annex VI to CLP, REACH Candidate List of SVHCs, and Directive 2000/54/EC's Annex III (Biological Agents list).
Last updated 26 srpnja 2024. Database contains 4917 unique substances/entries.
Filter the list
|
An inorganic pigment that is the reaction product of high temperature calcination in which nickel (II) oxide and silicon oxide in varying amounts are homogeneously and ionically interdiffused to form a crystalline matrix of olivine. Its composition may include any one or a combination of the modifiers alkali or alkaline earth halides.
|
271-112-7
|
68515-84-4
|
Carc. 1A; STOT RE 1; Skin Sens. 1 |
Details | ||
|
214-197-8
|
1113-02-6
|
Acute Tox. 3; Acute Tox. 4 |
Details | |||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
-
|
-
|
P Parasites |
Details | |||
|
-
|
-
|
P Parasites |
Details | |||
|
-
|
-
|
P Parasites |
Details | |||
|
215-235-6
|
1314-41-6
|
R Toxic for reproduction (article 57c) |
Details | |||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
show/hide
Turpentine, Venice, sulfurized, reaction products with hydrogen tetrachloroaurate(-1), sulfurized turpentine oil and mercurous nitrate, mixed with mercurous oxide
EC / List no:
293-784-0
| CAS no:
91082-69-8
Benzenesulfonic acid, 4-hydroxy-3,5-diiodo-, mercury(2+) salt (1:1)
EC / List no:
-
| CAS no:
515-43-5
[μ-[[4,4'-(oxydiethylene) bis(dodecenylsuccinato)](2-)]]diphenyldimercury
EC / List no:
299-418-6
| CAS no:
93882-20-3
Mercurate(1-), [dodecenylbutanedioato(2-)-O']phenyl-, hydrogen
EC / List no:
304-575-1
| CAS no:
94276-88-7
Hydrogen [metasilicato(2-)-O](2-methoxyethyl)mercurate(1-)
EC / List no:
264-920-6
| CAS no:
64491-92-5
Hydrogen triiodomercurate(1-), compound with 3-methyl-3H-benzothiazol-2-imine (1:1)
EC / List no:
276-613-4
| CAS no:
72379-35-2
[μ-[(oxydiethylene but-2-enedioato)(2-)]]diphenyldimercury
EC / List no:
301-791-8
| CAS no:
94070-92-5
[2,2',2''-nitrilotri(ethanol)-N,O,O',O'']phenylmercury lactate
EC / List no:
245-581-3
| CAS no:
23319-66-6
Mercury, phenyl((2-phenyldiazenecarbothioic acid-kappaS) 2-phenylhydrazidato-kappaN2)-
EC / List no:
-
| CAS no:
12406-51-8
Bis(acetato-O)[μ-(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthene]-2',7'-diyl)]dimercury
EC / List no:
222-673-1
| CAS no:
3570-80-7
(2',7'-dibromo-3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-4'-yl)hydroxymercury
EC / List no:
259-779-2
| CAS no:
55728-51-3
(4-((4-(Dimethylamino)phenyl)azo)phenyl)mercuric acetate
EC / List no:
631-561-5
| CAS no:
19447-62-2
Cyclopentanecarboxylic acid, 3-(((3-mercapto-2-methoxypropyl)amino)carbonyl)-2,2,3-trimethyl-, mercury complex
EC / List no:
-
| CAS no:
76-31-3
Tetrakis(acetato-O)[μ4-(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthene]-2',4',5',7'-tetrayl)]tetramercury
EC / List no:
259-075-5
| CAS no:
54295-90-8
Bis(acetato-O)[μ-[1,3-dioxane-2,5-diylbis(methylene)-C:C',O,O']]dimercury
EC / List no:
281-717-8
| CAS no:
84029-43-6
Butanoic acid, 4-((((2-methoxypropyl)amino)carbonyl)amino)-4-oxo-, mercury complex
EC / List no:
-
| CAS no:
72-58-2
Diphenyl[μ-[(tetrapropenyl)succinato(2-)-O:O']]dimercury
EC / List no:
248-355-2
| CAS no:
27236-65-3
Mercury, (acetato-kappaO)(3-(chloromethoxy-kappaO)propyl-kappaC)-
EC / List no:
-
| CAS no:
1319-86-4
Mercury, (3-((((3-carboxy-1-oxopropyl)amino)carbonyl)amino)-2-methoxypropyl)hydroxy-
EC / List no:
-
| CAS no:
140-20-5
Hydrogen [3-[(α-carboxylato-o-anisoyl)amino]-2-hydroxypropyl]hydroxymercurate(1-)
EC / List no:
247-796-8
| CAS no:
26552-50-1
Hydrogen μ-hydroxy[μ-[orthoborato(3-)-O:O']]diphenyldimercurate(1-)
EC / List no:
304-637-8
| CAS no:
94277-53-9
2-hydroxy-5-(1,1,3,3-tetramethylbutyl)phenylmercury acetate
EC / List no:
209-534-0
| CAS no:
584-18-9
Mercury, (3-(2,5-dioxo-1-pyrrolidinyl)-2-methoxypropyl)hydroxy-, compd. with 3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione (1:1)
EC / List no:
-
| CAS no:
747-23-9
Sodium [3-[[(3-carboxylatopropionamido)carbonyl]amino]-2-methoxypropyl]hydroxymercurate(1-)
EC / List no:
231-532-3
| CAS no:
7620-30-6
[2,5-dichloro-3,6-dihydroxy-2,5-cyclohexadiene-1,4-dionato(2-)-O1,O6]mercury
EC / List no:
251-672-9
| CAS no:
33770-60-4
|
-
|
-
|
Acute Tox. 2; Acute Tox. 1; STOT RE 2 |
Details | ||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
237-560-2
|
13840-56-7
|
Repr. 1B |
R Toxic for reproduction (article 57c) |
Details | ||
|
244-058-7
|
20816-12-0
|
Acute Tox. 2; Acute Tox. 1; Skin Corr. 1B |
Details | |||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
211-139-3
|
630-60-4
|
Acute Tox. 3; STOT RE 2 |
Details | |||
|
254-637-6
|
39807-15-3
|
Repr. 2; STOT RE 2 |
Details | |||
|
205-634-3
|
144-62-7
|
Acute Tox. 4 |
Details | |||
|
202-464-1
|
95-92-1
|
Acute Tox. 4; Eye Irrit. 2 |
Details | |||
|
243-867-2
|
20543-06-0
|
Carc. 1A; STOT RE 1; Skin Sens. 1 |
Details | |||
|
207-306-5
|
460-19-5
|
Press. Gas; Flam. Gas 1; Acute Tox. 3 |
Details | |||
|
245-445-3
|
23135-22-0
|
Acute Tox. 2; Acute Tox. 4 |
Details | |||
|
604-430-5
|
144651-06-9
|
STOT RE 2 |
Details | |||
|
271-846-8
|
68609-97-2
|
Skin Irrit. 2; Skin Sens. 1 |
Details | |||
|
DAISO CCS-1S-E; S-GLYTO
|
417-210-7
|
70987-78-9
|
Carc. 1B; Muta. 2; Eye Dam. 1; Skin Sens. 1 |
Details | ||
|
LUCHEM HA-R 100; LUPERSOL HA-R 100
|
413-230-5
|
122035-71-6
|
Eye Dam. 1; Skin Sens. 1 |
Details | ||
|
226-066-2
|
5259-88-1
|
Acute Tox. 4 |
Details | |||
|
206-110-7
|
301-12-2
|
Acute Tox. 3 |
Details | |||
|
203-430-9
|
106-75-2
|
Acute Tox. 4; Skin Irrit. 2; Eye Dam. 1 |
Details | |||
|
211-745-8
|
693-21-0
|
Expl. 1.1; Acute Tox. 2; Acute Tox. 1; STOT RE 2 |
Details | |||
|
211-745-8
|
693-21-0
|
Unst. Expl.; Acute Tox. 2; Acute Tox. 1; STOT RE 2 |
Details | |||
|
219-679-1
|
2497-07-6
|
Acute Tox. 2; Acute Tox. 3 |
Details | |||
|
231-956-9
|
7782-44-7
|
Ox. Gas 1; Press. Gas |
Details | |||
|
250-339-5
|
30784-30-6
|
ENDE Endocrine disrupting properties (Article 57(f) - environment) |
Details | |||
|
201-280-9
|
80-46-6
|
ENDE Endocrine disrupting properties (Article 57(f) - environment) |
Details | |||
|
241-427-4
|
17404-66-9
|
ENDE Endocrine disrupting properties (Article 57(f) - environment) |
Details | |||
|
203-254-2
|
104-94-9
|
Acute Tox. 2; Acute Tox. 1; STOT RE 2 |
Details | |||
|
203-405-2
|
106-51-4
|
Acute Tox. 3; Eye Irrit. 2; STOT SE 3; Skin Irrit. 2 |
Details | |||
|
203-398-6
|
106-44-5
|
Acute Tox. 3; Skin Corr. 1B |
Details | |||
|
247-770-6
|
26543-97-5
|
ENDE Endocrine disrupting properties (Article 57(f) - environment) |
Details | |||
|
202-795-1
|
99-86-5
|
Flam. Liq. 3; Acute Tox. 4; Skin Sens. 1; Asp. Tox. 1 |
Details | |||
|
202-810-1
|
100-01-6
|
Acute Tox. 3; STOT RE 2 |
Details | |||
|
203-199-4
|
104-40-5
|
ENDE Endocrine disrupting properties (Article 57(f) - environment) |
Details | |||
|
203-404-7
|
106-50-3
|
Acute Tox. 3; Eye Irrit. 2; Skin Sens. 1 |
Details | |||
|
203-180-0
|
104-15-4
|
Skin Corr. 1B |
Details | |||
|
203-180-0
|
104-15-4
|
Eye Irrit. 2; STOT SE 3; Skin Irrit. 2 |
Details | |||
|
203-403-1
|
106-49-0
|
Carc. 2; Acute Tox. 3; Eye Irrit. 2; Skin Sens. 1 |
Details | |||
|
UP 565
|
411-530-0
|
15024-10-9
|
Skin Sens. 1 |
Details | ||
|
203-396-5
|
106-42-3
|
Flam. Liq. 3; Acute Tox. 4; Skin Irrit. 2 |
Details | |||
|
616-379-6
|
76738-62-0
|
Repr. 2; Acute Tox. 4; Eye Irrit. 2 |
Details | |||
|
232-627-2
|
9001-73-4
|
Eye Irrit. 2; STOT SE 3; Skin Irrit. 2; Resp. Sens. 1 |
Details | |||
|
200-397-2
|
58-74-2
|
Acute Tox. 4 |
Details | |||
|
-
|
-
|
F Fungi |
Details | |||
|
A complex combination of hydrocarbons obtained from a catalytic dewaxing process. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C20 through C50 and produces a finished oil with a viscosity of at least 100 SUS at 100°F (19cSt at 40°C).
|
265-174-4
|
64742-70-7
|
Carc. 1B |
Details | ||
|
A complex combination of hydrocarbons obtained from a catalytic dewaxing process. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C15 through C30 and produces a finished oil with a viscosity of less than 100 SUS at 100°F (19cSt at 40°C).
|
265-176-5
|
64742-71-8
|
Carc. 1B |
Details | ||
|
A complex combination of hydrocarbons obtained from sulfur-containing paraffinic crude oil. It consists predominantly of a solvent refined deparaffinated lubricating oil with a viscosity of 65cSt at 50°C.
|
295-810-6
|
92129-09-4
|
Carc. 1B |
Details | ||
|
287-196-3
|
85422-92-0
|
PBT Persistent, Bioaccumulative and Toxic (article 57d) VPVB very Persistent and very Bioaccumulative (article 57e) |
Details | |||
|
A complex combination of hydrocarbons obtained by the treatment of lignite carbonization tar with bentonite for removal of trace constituents and impurities. It consists predominantly of saturated straight and branched chain hydrocarbons having carbon numbers predominantly greater than C12.
|
308-297-1
|
97926-77-7
|
Carc. 1B |
Details | ||
|
A complex combination of hydrocarbons obtained by the treatment of lignite carbonization tar with silicic acid for removal of trace constituents and impurities. It consists predominantly of saturated straight and branched chain hydrocarbons having carbon numbers predominantly greater than C12.
|
308-298-7
|
97926-78-8
|
Carc. 1B |
Details | ||
|
A complex combination of hydrocarbons obtained by the treatment of lignite carbonization tar with activated carbon for removal of trace constituents and impurities. It consists predominantly of saturated straight and branched chain hydrocarbons having carbon numbers predominantly greater than C12.
|
308-296-6
|
97926-76-6
|
Carc. 1B |
Details | ||
|
A complex combination of hydrocarbons obtained from liqnite carbonization tar by solvent crystallisation (solvent deoiling), by sweating or an adducting process treated with hydrogen in the presence of a catalyst. It consists predominantly of straight and branched chain saturated hydrocarbons having carbon numbers predominantly greater than C12.
|
295-455-7
|
92045-72-2
|
Carc. 1B |
Details | ||
|
A complex combination of hydrocarbons obtained from liqnite carbonization tar by solvent crystallisation (solvent deoiling), by sweating or an adducting process. It consists predominantly of straight and branched chain saturated hydrocarbons having carbon numbers predominantly greater than C12.
|
295-454-1
|
92045-71-1
|
Carc. 1B |
Details | ||
|
307-202-0
|
97553-43-0
|
PBT Persistent, Bioaccumulative and Toxic (article 57d) VPVB very Persistent and very Bioaccumulative (article 57e) |
Details | |||
|
-
|
-
|
P Parasites |
Details | |||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
217-615-7
|
1910-42-5
|
Acute Tox. 2; Acute Tox. 3; STOT RE 1; Eye Irrit. 2; STOT SE 3; Skin Irrit. 2 |
Details | |||
|
218-196-3
|
2074-50-2
|
Acute Tox. 2; Acute Tox. 3; STOT RE 1; Eye Irrit. 2; STOT SE 3; Skin Irrit. 2 |
Details | |||
|
200-271-7
|
56-38-2
|
Acute Tox. 2; Acute Tox. 3; STOT RE 1 |
Details | |||
|
206-050-1
|
298-00-0
|
Flam. Liq. 3; Acute Tox. 2; Acute Tox. 3; STOT RE 2 |
Details | |||
|
-
|
-
|
B Bacteria and similar species |
Details | |||
|
-
|
-
|
B Bacteria and similar species |
Details | |||
|
214-215-4
|
1114-71-2
|
Acute Tox. 4 |
Details | |||
|
266-275-6
|
66246-88-6
|
Repr. 2; Acute Tox. 4 |
Details | |||
|
254-938-2
|
40487-42-1
|
Repr. 2 |
Details | |||
|
-
|
-
|
F Fungi |
Details | |||
|
210-172-0
|
608-93-5
|
Flam. Sol. 1; Acute Tox. 4 |
Details | |||
|
200-925-1
|
76-01-7
|
Carc. 2; STOT RE 1 |
Details | |||
|
201-778-6
|
87-86-5
|
Carc. 2; Acute Tox. 2; Acute Tox. 3; Eye Irrit. 2; STOT SE 3; Skin Irrit. 2 |
Details | |||
|
276-745-2
|
72629-94-8
|
VPVB very Persistent and very Bioaccumulative (article 57e) |
Details | |||
|
225-644-1
|
4986-89-4
|
Eye Irrit. 2; Skin Irrit. 2; Skin Sens. 1 |
Details | |||
|
201-084-3
|
78-11-5
|
Expl. 1.1 |
Details | |||
|
201-084-3
|
78-11-5
|
Unst. Expl. |
Details | |||
|
222-540-8
|
3524-68-3
|
Eye Irrit. 2; Skin Irrit. 2; Skin Sens. 1 |
Details | |||
|
426-590-3
|
187412-41-5
|
Skin Sens. 1 |
Details | |||
|
235-067-7
|
12065-90-6
|
R Toxic for reproduction (article 57c) |
Details | |||
|
202-490-3
|
96-22-0
|
Flam. Liq. 2; STOT SE 3 |
Details | |||
|
203-692-4
|
109-66-0
|
Flam. Liq. 2; Asp. Tox. 1; STOT SE 3 |
Details | |||
|
204-634-0
|
123-54-6
|
Flam. Liq. 3; Acute Tox. 4 |
Details | |||
|
250-378-8
|
30899-19-5
|
Flam. Liq. 3; Acute Tox. 4; STOT SE 3 |
Details | |||
|
404-290-3
|
7216-95-7
|
Repr. 1B; Acute Tox. 4; STOT RE 2; Eye Irrit. 2 |
Details | |||
|
418-270-7
|
-
|
Skin Sens. 1 |
Details | |||
|
205-391-3
|
140-01-2
|
Repr. 1B; Acute Tox. 4; STOT RE 2 |
Details | |||
|
REACTIVE NAVY BLUE 9411; SUMIFIX SUPRA MARINE BNF GRANULES
|
423-790-2
|
1379676-74-0
|
Eye Dam. 1; Skin Sens. 1 |
Details | ||
|
301-312-2
|
93983-23-4
|
Eye Irrit. 2 |
Details | |||
|
436-920-8
|
172399-10-9
|
Eye Dam. 1 |
Details | |||
|
OLIVE-GREEN JB 1170
|
419-210-2
|
178452-71-6
|
Eye Dam. 1 |
Details | ||
|
414-910-4
|
-
|
Eye Dam. 1; Skin Sens. 1 |
Details | |||
|
442-030-0
|
321912-47-4
|
Eye Dam. 1 |
Details | |||
|
256-418-0
|
49663-84-5
|
C Carcinogenic (article 57a) |
Details | |||
|
215-320-8
|
1321-64-8
|
Acute Tox. 4; Eye Irrit. 2; Skin Irrit. 2 |
Details | |||
|
211-047-3
|
628-63-7
|
Flam. Liq. 3 |
Details | |||
|
211-340-6
|
638-49-3
|
Flam. Liq. 3; Eye Irrit. 2; STOT SE 3 |
Details | |||
|
207-332-7
|
463-04-7
|
Flam. Liq. 2; Acute Tox. 4 |
Details | |||
|
210-852-7
|
624-54-4
|
Flam. Liq. 3 |
Details | |||
|
232-629-3
|
9001-75-6
|
Eye Irrit. 2; STOT SE 3; Skin Irrit. 2; Resp. Sens. 1 |
Details | |||
|
-
|
-
|
B Bacteria and similar species |
Details | |||
|
201-186-8
|
79-21-0
|
Flam. Liq. 3; Org. Perox. D; Acute Tox. 4; Skin Corr. 1A |
Details | |||
|
603-902-8
|
13517-20-9
|
Repr. 1B; STOT SE 3; Eye Dam. 1 |
Details | |||
|
603-902-8
|
13517-20-9
|
R Toxic for reproduction (article 57c) |
Details | |||
|
603-902-8
|
13517-20-9
|
Repr. 1B; Acute Tox. 4; STOT SE 3; Eye Dam. 1 |
Details | |||
|
600-611-8
|
10486-00-7
|
Repr. 1B; STOT SE 3; Eye Dam. 1 |
Details | |||
|
600-611-8
|
10486-00-7
|
R Toxic for reproduction (article 57c) |
Details | |||
|
600-611-8
|
10486-00-7
|
Repr. 1B; Acute Tox. 4; STOT SE 3; Eye Dam. 1 |
Details | |||
|
600-419-4
|
10332-33-9
|
R Toxic for reproduction (article 57c) |
Details | |||
|
600-419-4
|
10332-33-9
|
Ox. Sol. 3; Repr. 1B; Acute Tox. 4; STOT SE 3; Eye Dam. 1 |
Details | |||
|
600-419-4
|
10332-33-9
|
Ox. Sol. 3; Repr. 1B; Acute Tox. 3; Acute Tox. 4; STOT SE 3; Eye Dam. 1 |
Details | |||
|
234-390-0
|
11138-47-9;12040-72-1;37244-98-7
|
R Toxic for reproduction (article 57c) |
Details | |||
|
234-390-0
|
11138-47-9;12040-72-1;37244-98-7
|
Ox. Sol. 3; Repr. 1B; Acute Tox. 3; Acute Tox. 4; STOT SE 3; Eye Dam. 1 |
Details | |||
|
234-390-0
|
11138-47-9;12040-72-1;37244-98-7
|
Repr. 1B; Acute Tox. 4; STOT SE 3; Eye Dam. 1 |
Details | |||
|
234-390-0
|
11138-47-9;12040-72-1;37244-98-7
|
Ox. Sol. 3; Repr. 1B; Acute Tox. 3; Acute Tox. 4; STOT SE 3; Eye Dam. 1 |
Details | |||
|
234-390-0
|
11138-47-9;12040-72-1;37244-98-7
|
R Toxic for reproduction (article 57c) |
Details | |||
|
234-390-0
|
11138-47-9;12040-72-1;37244-98-7
|
R Toxic for reproduction (article 57c) |
Details | |||
|
234-390-0
|
11138-47-9;12040-72-1;37244-98-7
|
Ox. Sol. 3; Repr. 1B; Acute Tox. 4; STOT SE 3; Eye Dam. 1 |
Details | |||
|
234-390-0
|
11138-47-9;12040-72-1;37244-98-7
|
Repr. 1B; STOT SE 3; Eye Dam. 1 |
Details | |||
|
234-390-0
|
11138-47-9;12040-72-1;37244-98-7
|
Ox. Sol. 3; Repr. 1B; Acute Tox. 4; STOT SE 3; Eye Dam. 1 |
Details | |||
|
231-512-4
|
7601-90-3
|
Ox. Liq. 1; Skin Corr. 1A |
Details | |||
|
253-718-3
|
37924-13-3
|
Acute Tox. 4; Eye Irrit. 2 |
Details | |||
|
206-793-1
|
375-73-5
|
HH Equivalent level of concern having probable serious effects to human health (Article 57(f) - human health) E Equivalent level of concern having probable serious effects to the environment (Article 57(f) - environment) |
Details | |||
|
show/hide
|
-
|
-
|
R Toxic for reproduction (article 57c) PBT Persistent, Bioaccumulative and Toxic (article 57d) VPVB very Persistent and very Bioaccumulative (article 57e) HH Equivalent level of concern having probable serious effects to human health (Article 57(f) - human health) E Equivalent level of concern having probable serious effects to the environment (Article 57(f) - environment) |
Details | ||
|
206-798-9
|
375-85-9
|
Repr. 1B; STOT RE 1 |
R Toxic for reproduction (article 57c) PBT Persistent, Bioaccumulative and Toxic (article 57d) VPVB very Persistent and very Bioaccumulative (article 57e) HH Equivalent level of concern having probable serious effects to human health (Article 57(f) - human health) E Equivalent level of concern having probable serious effects to the environment (Article 57(f) - environment) |
Details | ||
|
206-587-1
|
355-46-4
|
VPVB very Persistent and very Bioaccumulative (article 57e) |
Details | |||
|
206-801-3
|
375-95-1
|
Carc. 2; Repr. 1B; Lact.; Acute Tox. 4; STOT RE 1; Eye Dam. 1 |
R Toxic for reproduction (article 57c) PBT Persistent, Bioaccumulative and Toxic (article 57d) |
Details | ||
|
-
|
21049-39-8
|
Carc. 2; Repr. 1B; Lact.; Acute Tox. 4; STOT RE 1; Eye Dam. 1 |
R Toxic for reproduction (article 57c) PBT Persistent, Bioaccumulative and Toxic (article 57d) |
Details | ||
|
217-179-8
|
1763-23-1
|
Carc. 2; Repr. 1B; STOT RE 1; Acute Tox. 4; Lact. |
Details | |||
|
206-397-9
|
335-67-1
|
Carc. 2; Repr. 1B; Lact.; Acute Tox. 4; STOT RE 1; Eye Dam. 1 |
R Toxic for reproduction (article 57c) PBT Persistent, Bioaccumulative and Toxic (article 57d) |
Details | ||
|
258-067-9
|
52645-53-1
|
Acute Tox. 4; Skin Sens. 1 |
Details | |||
|
600-765-6
|
106700-29-2
|
Acute Tox. 4; Skin Sens. 1 |
Details | |||
|
A complex combination of hydrocarbons obtained when petrolatum is treated with Al2O3 to remove polar components and impurities. It consists predominantly of saturated, crystalline, and liquid hydrocarbons having carbon numbers predominantly greater than C25.
|
285-098-5
|
85029-74-9
|
Carc. 1B |
Details | ||
|
A complex combination of hydrocarbons obtained by the treatment of petroleum petrolatum with activated carbon for the removal of trace polar constituents and impurities. It consists predominantly of saturated hydrocarbons having carbon numbers predominantly greater than C20.
|
308-149-6
|
97862-97-0
|
Carc. 1B |
Details | ||
|
A complex combination of hydrocarbons obtained by treatment of petrolatum with bleaching earth for the removal of traces of polar constituents and impurities. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of greater than C25.
|
309-706-6
|
100684-33-1
|
Carc. 1B |
Details | ||
|
A complex combination of hydrocarbons obtained as a semi-solid from dewaxed paraffinic residual oil treated with hydrogen in the presence of a catalyst. It consists predominantly of saturated microcrystalline and liquid hydrocarbons having carbon numbers predominantly greater than C20.
|
295-459-9
|
92045-77-7
|
Carc. 1B |
Details | ||
|
A complex combination of organic compounds, predominantly high molecular weight carboxylic acids, obtained by the air oxidation of petrolatum.
|
265-206-7
|
64743-01-7
|
Carc. 1B |
Details | ||
|
A complex combination of hydrocarbons obtained by the treatment of petroleum petrolatum with silicic acid for the removal of trace polar constituents and impurities. It consists predominantly of saturated hydrocarbons having carbon numbers predominantly greater than C20.
|
308-150-1
|
97862-98-1
|
Carc. 1B |
Details | ||
|
A complex combination of hydrocarbons obtained as a semi-solid from dewaxing paraffinic residual oil. It consists predominantly of saturated crystalline and liquid hydrocarbons having carbon numbers predominantly greater than C25.
|
232-373-2
|
8009-03-8
|
Carc. 1B |
Details | ||
|
A complex combination of hydrocarbons obtained by subjecting a liquified petroleum gas mix to a sweetening process to oxidize mercaptans or to remove acidic impurities. It consists predominantly of C4 saturated and unsaturated hydrocarbons.
|
295-463-0
|
92045-80-2
|
Press. Gas; Flam. Gas 1; Carc. 1A; Muta. 1B |
Details | ||
|
A complex combination of hydrocarbons obtained by subjecting liquefied petroleum gas mix to a sweetening process to convert mercaptans or to remove acidic impurities. It consists of hydrocarbons having carbon numbers predominantly in the range of C3 through C7 and boiling in the range of approximately -40°C to 80°C (-40°F to 176°F).
|
270-705-8
|
68476-86-8
|
Press. Gas; Flam. Gas 1; Carc. 1A; Muta. 1B |
Details | ||
|
A complex combination of hydrocarbons produced by the distillation of crude oil. It consists of hydrocarbons having carbon numbers predominantly in the range of C3 through C7 and boiling in the range of approximately -40°C to 80°C (-40°F to 176°F).
|
270-704-2
|
68476-85-7
|
Press. Gas; Flam. Gas 1; Carc. 1A; Muta. 1B |
Details | ||
|
The complex combination of hydrocarbons obtained in a hydrofiner-powerformer process and boiling in a range of approximately 27°C to 210°C (80°F to 410°F).
|
271-058-4
|
68514-79-4
|
Carc. 1B; Muta. 1B; Asp. Tox. 1 |
Details | ||
|
A complex combination which consists primarily of hydrogen with various small amounts of methane, ethane, and propane.
|
271-750-6
|
68607-11-4
|
Press. Gas; Flam. Gas 1; Carc. 1A; Muta. 1B |
Details | ||
|
A complex combination of hydrocarbons. It consists predominantly of aliphatic, alicyclic and aromatic hydrocarbons. It may also contain small amounts of nitrogen, oxygen and sulfur compounds. This category encompasses light, medium, and heavy petroleums, as well as the oils extracted from tar sands. Hydrocarbonaceous materials requiring major chemical changes for their recovery or conversion to petroleum refinery feedstocks such as crude shale oils, upgraded shale oils and liquid coal fuels are not included in this definition.
|
232-298-5
|
8002-05-9
|
Carc. 1B |
Details | ||
|
201-581-5
|
85-01-8
|
VPVB very Persistent and very Bioaccumulative (article 57e) |
Details | |||
|
Residue from the distillation of crude phenanthrene boiling in the approximate range of 340°C to 420°C (644°F to 788°F). It consists predominantly of phenanthrene, anthracene and carbazole.
|
310-169-5
|
122070-78-4
|
Carc. 1B |
Details | ||
|
218-892-7
|
2275-14-1
|
Acute Tox. 3 |
Details | |||
|
-
|
-
|
R Toxic for reproduction (article 57c) ENDE Endocrine disrupting properties (Article 57(f) - environment) END Endocrine disrupting properties (Article 57(f) - human health) |
Details | |||
|
616-100-8
|
74499-35-7
|
Repr. 1B; Skin Corr. 1C; Eye Dam. 1 |
R Toxic for reproduction (article 57c) ENDE Endocrine disrupting properties (Article 57(f) - environment) END Endocrine disrupting properties (Article 57(f) - human health) |
Details | ||
|
701-105-0
|
1801269-80-6
|
Repr. 1B; Skin Corr. 1C; Eye Dam. 1 |
Details | |||
|
701-107-1
|
1801269-77-1
|
Repr. 1B; Skin Corr. 1C; Eye Dam. 1 |
Details | |||
|
640-104-9
|
210555-94-5
|
Repr. 1B; Skin Corr. 1C; Eye Dam. 1 |
R Toxic for reproduction (article 57c) ENDE Endocrine disrupting properties (Article 57(f) - environment) END Endocrine disrupting properties (Article 57(f) - human health) |
Details | ||
|
608-492-4
|
3050-88-2
|
ENDE Endocrine disrupting properties (Article 57(f) - environment) |
Details | |||
|
310-154-3
|
121158-58-5
|
Repr. 1B; Skin Corr. 1C; Eye Dam. 1 |
R Toxic for reproduction (article 57c) ENDE Endocrine disrupting properties (Article 57(f) - environment) END Endocrine disrupting properties (Article 57(f) - human health) |
Details | ||
|
310-154-3
|
121158-58-5
|
R Toxic for reproduction (article 57c) ENDE Endocrine disrupting properties (Article 57(f) - environment) END Endocrine disrupting properties (Article 57(f) - human health) |
Details | |||
|
310-154-3
|
121158-58-5
|
R Toxic for reproduction (article 57c) ENDE Endocrine disrupting properties (Article 57(f) - environment) END Endocrine disrupting properties (Article 57(f) - human health) |
Details | |||
|
show/hide
|
799-972-3
|
-
|
R Toxic for reproduction (article 57c) ENDE Endocrine disrupting properties (Article 57(f) - environment) END Endocrine disrupting properties (Article 57(f) - human health) |
Details | ||
|
276-743-1
|
72624-02-3
|
ENDE Endocrine disrupting properties (Article 57(f) - environment) |
Details | |||
|
270-966-8
|
68512-30-1
|
VPVB very Persistent and very Bioaccumulative (article 57e) |
Details | |||
|
291-844-0
|
90481-04-2
|
ENDE Endocrine disrupting properties (Article 57(f) - environment) |
Details | |||
|
-
|
-
|
R Toxic for reproduction (article 57c) ENDE Endocrine disrupting properties (Article 57(f) - environment) END Endocrine disrupting properties (Article 57(f) - human health) |
Details | |||
|
-
|
57427-55-1
|
R Toxic for reproduction (article 57c) ENDE Endocrine disrupting properties (Article 57(f) - environment) END Endocrine disrupting properties (Article 57(f) - human health) |
Details | |||
|
203-632-7
|
108-95-2
|
Muta. 2; Acute Tox. 3; STOT RE 2; Skin Corr. 1B |
Details | |||
|
201-004-7
|
77-09-8
|
Carc. 1B; Muta. 2; Repr. 2 |
C Carcinogenic (article 57a) |
Details | ||
|
The combination of phenols extracted, using isobutyl acetate, from the ammonia liquor condensed from the gas evolved in low-temperature (less than 700°C (1292°F)) destructive distillation of coal. It consists predominantly of a mixture of monohydric and dihydric phenols.
|
284-881-9
|
84988-93-2
|
Carc. 1B; Muta. 1B |
Details | ||
|
293-435-2
|
91079-47-9
|
Carc. 1B; Muta. 1B |
Details | |||
|
219-997-0
|
2597-03-7
|
Acute Tox. 4 |
Details | |||
|
CGI 819
|
423-340-5
|
162881-26-7
|
Skin Sens. 1A |
Details | ||
|
204-557-2
|
122-60-1
|
Carc. 1B; Muta. 2; Acute Tox. 4; STOT SE 3; Skin Irrit. 2; Skin Sens. 1 |
Details | |||
|
DPX-E6758
|
406-600-2
|
89392-03-0
|
Skin Sens. 1 |
Details | ||
|
202-873-5
|
100-63-0
|
Carc. 1B; Muta. 2; Acute Tox. 3; STOT RE 1; Eye Irrit. 2; Skin Irrit. 2; Skin Sens. 1 |
Details | |||
|
248-259-0
|
27140-08-5
|
Carc. 1B; Muta. 2; Acute Tox. 3; STOT RE 1; Eye Irrit. 2; Skin Irrit. 2; Skin Sens. 1 |
Details | |||
|
200-444-7
|
59-88-1
|
Carc. 1B; Muta. 2; Acute Tox. 3; STOT RE 1; Eye Irrit. 2; Skin Irrit. 2; Skin Sens. 1 |
Details | |||
|
257-622-2
|
52033-74-6
|
Carc. 1B; Muta. 2; Acute Tox. 3; STOT RE 1; Eye Irrit. 2; Skin Irrit. 2; Skin Sens. 1 |
Details | |||
|
200-532-5
|
62-38-4
|
Acute Tox. 3; STOT RE 1; Skin Corr. 1B |
Details | |||
|
202-866-7
|
100-57-2
|
Acute Tox. 3; STOT RE 1; Skin Corr. 1B |
Details | |||
|
200-242-9
|
55-68-5
|
Acute Tox. 3; STOT RE 1; Skin Corr. 1B |
Details | |||
|
206-052-2
|
298-02-2
|
Acute Tox. 1; Acute Tox. 2 |
Details | |||
|
223-874-7
|
4104-14-7
|
Acute Tox. 1; Acute Tox. 2 |
Details | |||
|
218-996-2
|
2310-17-0
|
Acute Tox. 3; Acute Tox. 4; Skin Sens. 1 |
Details | |||
|
213-423-2
|
947-02-4
|
Acute Tox. 1; Acute Tox. 2 |
Details | |||
|
200-870-3
|
75-44-5
|
Press. Gas; Acute Tox. 2; Skin Corr. 1B |
Details | |||
|
211-987-4
|
732-11-6
|
Repr. 2; Acute Tox. 4; Acute Tox. 3; STOT SE 1 |
Details | |||
|
-
|
5826-76-6
|
Acute Tox. 4 |
Details | |||
|
236-116-5
|
13171-21-6
|
Muta. 2; Acute Tox. 2; Acute Tox. 3 |
Details | |||
|
232-260-8
|
7803-51-2
|
Flam. Gas 1; Press. Gas; Acute Tox. 1; Skin Corr. 1B |
Details | |||
|
237-066-7
|
13598-36-2
|
Acute Tox. 4; Skin Corr. 1A |
Details | |||
|
231-633-2
|
7664-38-2
|
Skin Corr. 1B |
Details | |||
|
-
|
17169-61-8
|
Carc. 1A; STOT RE 1; Resp. Sens. 1; Skin Sens. 1 |
Details | |||